Triple Agonist Tracker

Direct Answer

A triple agonist is a medication that activates three separate hormone receptors at once, GLP-1, GIP, and glucagon, rather than just one. Retatrutide is currently the leading investigational triple agonist in development. DietApp.com lets you track triple- and dual-agonist medications alongside every standard GLP-1 medication in one place.

Triple Agonist vs. Dual Agonist vs. Single-Target GLP-1

Semaglutide (Ozempic, Wegovy) is a single-target GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual agonist, activating both GLP-1 and GIP receptors. Retatrutide goes further, activating GLP-1, GIP, and glucagon receptors simultaneously, the mechanism behind its informal "GLP-3" nickname, and clinical trials have shown this broader mechanism associated with substantial average weight loss.

Current Status

Retatrutide remains investigational, not FDA-approved, currently in Phase 3 trials under Eli Lilly's TRIUMPH program.

References

• Coskun T, et al. LY3437943, A Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist. Cell Metabolism (2022)

Related Resources

• What Is "GLP-3"? The Truth Behind This Trending Term
• Semaglutide vs. Tirzepatide
• The TRIUMPH Trials

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Download DietApp.com to track triple and dual agonist medications alongside your full GLP-1 treatment history.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This is for informational purposes only and is not medical advice.